StoneX Group reported Q2 fiscal 2026 results on May 6 that blew past expectations. EPS hit $2.07 against a $1.33 estimate, and revenue came in at $1.57 billion versus a consensus of $653 million. The tension worth watching is that executives were aggressive sellers into the very rally that preceded the beat.
Insider activity across the past 90 days has been overwhelmingly one-directional. The net value of insider selling over the period reached roughly $26.3 million, with net shares sold approaching 236,000. The CEO, Philip Andrew Smith, sold 30,000 shares at $92.23 on April 10 for nearly $2.8 million. Executive Vice Chairman Sean O'Connor sold 44,269 shares at $77.95 on March 31 — close to $3.5 million — after selling a further 40,000 shares in February at around $124.56 for nearly $5 million. The CIO, President, and two directors also sold material positions in the same window. That is a broad and persistent distribution of stock across the C-suite and board, taking place as the price climbed from the mid-$70s toward $108.
Short positioning tells a less alarming story. SI runs at 6.1% of the free float — elevated but not extreme — and has been drifting lower. It fell roughly 1.8% on the week and is down about 4.5% over the past month, ending at around 3.18 million shares short. Cost to borrow is negligible at 0.41%, down about 11% on the week. Borrow availability remains loose, with lending demand at just 12% of available supply — well off the 52-week tightest level of 15.4%. There is no squeeze pressure here. The ORTEX short score of 43.6 is mid-range and has been edging lower over the past two weeks, consistent with shorts quietly reducing rather than building.
Options traders are notably bullish. The put/call ratio dropped to 0.40 on May 5, well below its 20-day average of 0.55 — sitting nearly one standard deviation beneath the mean. That is directionally the most call-heavy posture in weeks. The 52-week range on the PCR runs from zero to 2.05, so a reading of 0.40 skews toward the optimistic end of the distribution. Given the earnings beat landed the same evening, it is plausible that call accumulation ahead of results was anticipatory — the PCR compression into the print lined up squarely with the subsequent outperformance.
On the Street, coverage remains thin. Jefferies, in February, lifted its target to $122 while keeping a Buy rating — that is the freshest rated action in the data set. William Blair initiated at Outperform in March 2025. The consensus price target is around $107, which was essentially in line with where the stock closed at $108.06 before the earnings release. Post-results, that target likely looks stale. The closest peer comparison worth noting: IBKR — a natural brokerage analog — gained 8.3% on the week, the strongest performer in the peer set. LAZ fell 7% over the same period, illustrating divergence within the financial-services cohort. SNEX's 3% weekly gain looks modest in retrospect, given the magnitude of the earnings beat that hit after market close.
Institutional ownership is stable and top-heavy. BlackRock added 490,000 shares to bring its stake to 13.3% of outstanding. Vanguard built by nearly 791,000 shares. Both moves were reported recently enough to be relevant. CEO O'Connor himself remains the fourth-largest holder at 5.3% of shares, even after the March sales — a concentration that gives insider activity here more weight than it might carry elsewhere.
The next data point that matters most is how the stock opens on May 7. The beat was large — EPS came in 56% above consensus — and the pre-earnings analyst target of $107 is now clearly behind the curve. Whether the Street revises targets meaningfully higher, and whether the insider selling pace continues at the post-earnings price level, are the two threads worth tracking in the sessions ahead.
See the live data behind this article on ORTEX.
Open SNEX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
